港股異動 | 績後獲券商唱好,石四藥集團放量升超9%
石四藥集團(2005.HK)大幅拉昇升超9%,股價重回5港元關口,暫成交2451萬港元較近期有所放量,總市值148億港元。公司昨日午間公吿,2023年股東應占溢利13.19億港元,同比增長17.44%。華泰證券維持石四藥“買入”評級,目標價6.48港元,看好業務多板塊開花。展望2024年,看好公司大輸液擴產銷售提速,安瓿/口服制劑集採放量,原料藥價格企穩訂單量恢復,預計公司2024年淨利潤同比增速超20%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.